A team of scientists and clinicians from the University of Pittsburgh have developed a novel form of eyedrops for the treatment of dry eye disease (DED). Harnessing the understanding of the underlying inflammatory pathways in DED, the team use cytokine IL-4 to tackle the underlying cause of the disease.